
APDN Earnings
Applied DNA Sciences Inc
- Overview
- Forecast
- Valuation
- Earnings
Earning Analysis
Welcome to our in-depth analysis of Applied DNA Sciences Inc(APDN) earnings, offering investors a detailed look into the company’s financial performance, revenue trends, earnings per share (EPS), and market reactions. This page provides a comprehensive overview of Applied DNA Sciences Inc earnings history, forecasts, and key financial metrics, empowering you with the data needed to make informed investment decisions. Whether you're tracking quarterly results, analyzing earnings surprises, or exploring future projections, our detailed breakdown covers it all.
Earnings Forecast
Revenue
EPS
Currency: USD
Actual
Estimate
Surprise Analysis
FY2025Q2 | 2025-05-15 | After Hours | - | - | - | 1.19M | 983.37K | -17.02 | -2.94 | -1.09 |
FY2025Q1 | 2025-02-13 | Pre-Market | -0.32 | -0.56 | -75.00 | 1.18M | 1.20M | +1.84 | -8.22 | -14.81 |
FY2024Q4 | 2024-12-17 | - | -0.33 | -0.32 | +3.03 | 899.00K | 813.11K | -9.55 | +24.46 | -9.85 |
FY2024Q2 | 2024-05-10 | - | -4.60 | -5.31 | -15.43 | 951.00K | 929.63K | -2.25 | -7.75 | -26.47 |
FY2024Q1 | 2024-02-08 | - | -0.31 | -0.09 | +70.97 | 776.00K | 891.16K | +14.84 | - | - |
FY2023Q4 | 2023-12-07 | - | -0.27 | -0.26 | +3.70 | 1.68M | 779.74K | -53.60 | -2.70 | -31.53 |
- | 2023-05-11 | - | -0.17 | -0.20 | -17.65 | - | - | - | -0.92 | +5.50 |
- | 2023-02-09 | - | -0.33 | -0.14 | +57.58 | - | - | - | -6.78 | -6.78 |
- | 2022-08-11 | - | -0.36 | -0.33 | +8.33 | - | - | - | -1.95 | -19.52 |
- | 2022-05-12 | - | -0.30 | -0.28 | +6.67 | - | - | - | +5.08 | +10.17 |
APDN Earnings Analysis
Our earnings analysis provides a granular look at the company’s performance across recent fiscal quarters, highlighting key metrics such as revenue, EPS, and operating margins. By examining actual results against analyst estimates, we uncover trends and surprises that drive stock price movements, offering valuable insights for both short-term traders and long-term investors.
In the most recent quarter, Applied DNA Sciences Inc reported performance for FY2025Q2, announced on 2025-05-15. The company achieved an EPS of , compared to analyst estimates of by % . Revenue for the quarter reached 983.37K compared to expectations of 1.19M by -17.02% .
The stock price reacted with a -2.94% one-day change and a -1.09% five-day change following the earnings release. These movements reflect market reaction in Applied DNA Sciences Inc growth trajectory and strategic initiatives.
APDN Earnings Forecast
Looking ahead, Applied DNA Sciences Inc(APDN) remains a focal point for investors seeking growth opportunities. Analyst forecasts for 2025/Q3 project quarter revenue of 1.28M and an EPS of .
However, recent estimate revisions provide additional context. Over the past three months, revenue estimates for FY2025 have been No Change by 0%, while EPS estimates have been No Change by 0%. For the upcoming , revenue estimates have been adjusted Go Down by -67.57% . These revisions correlate with a % change in stock price over the same period, suggesting potential buying opportunities for investors who believe in Applied DNA Sciences Inc long-term fundamentals.
The relationship between earnings forecast revisions and stock price movements is critical for investors. Positive revisions in revenue or EPS often signal strengthening fundamentals, making temporary price dips attractive entry points. Conversely, downward revisions may reflect short-term challenges.
Estimate Revision
The chart shows the correlation between APDN's stock price and earnings forecast revisions. Positive revisions in Revenue or EPS often strengthen the stock's fundamentals, making price dips potential buying opportunities.
Revenue Estimates for FY2025
No Change

0.00%
In Past 3 Month
Revenue Estimates for Q3 2025
No Change

0.00%
In Past 3 Month
Stock Price
Go Down

-67.57%
In Past 3 Month
1Y
3Y
5Y
Annual FY 2025
Currency: USD
1Y
3Y
5Y
--
Revenue Estimate-Annual FY 2025:5.28M
--
EPS Estimate-Annual FY 2025:0
—
Stock Price4.07
APDN Revenue and EPS Performance: A Historical Perspective
Applied DNA Sciences Inc revenue and earnings per share (EPS) performance over recent quarters provides a clear picture of its financial health. Below is a detailed breakdown of the company’s earnings history, showcasing actual results, analyst estimates, and surprise percentages for key fiscal quarters:
FY2025Q2 (2025-05-15,After Hours):
EPS: (Actual) vs. (Estimate) (%)
Revenue: 983.37K (Actual) vs. 1.19M (Estimate) (-17.02%)
Price Reaction: -2.94%(1-Day), -1.09%(5-Day)
FY2025Q1 (2025-02-13,Pre-Market):
EPS: -0.56 (Actual) vs.-0.32 (Estimate) (-75.00%)
Revenue: 1.20M (Actual) vs. 1.18M (Estimate) (1.84%)
Price Reaction: -8.22%(1-Day), -14.81%(5-Day)
FY2024Q4 (2024-12-17,):
EPS: -0.32 (Actual) vs.-0.33 (Estimate) (3.03%)
Revenue: 813.11K (Actual) vs. 899.00K (Estimate) (-9.55%)
Price Reaction: 24.46%(1-Day), -9.85%(5-Day)
Earnings Reaction
The chart below shows how APDN performed 10 days before and after its earnings report, based on data from the past quarters. Typically, APDN sees a -6.20% change in stock price 10 days leading up to the earnings, and a -18.98% change 10 days following the report. On the earnings day itself, the stock moves by -0.20%. This data can give you a slight idea of what to expect for the next quarter's release.
For example, in MAR/2025, the stock changed -17.28% on the day following the earnings release and then changed by -58.32% over the next 10 days. These patterns provide investors with valuable insights into potential price movements and help inform trading strategies around earnings events.
Transcript Summary
Negative
2025-02-13
The earnings call reveals multiple red flags: substantial going concern doubts, high cash burn, competitive pressures, and regulatory compliance challenges. Despite revenue growth and cost management improvements, the financial health remains precarious. The Q&A section highlights unclear management responses, especially regarding revenue opportunities. The workforce reduction charge and increased net loss further amplify concerns. These factors suggest a negative outlook, with potential stock decline due to financial instability and operational uncertainties.
Applied DNA Sciences, Inc. (APDN) Q3 2024 Earnings Call Summary
Negative
2024-08-11
The earnings call summary highlights several concerns: substantial revenue decline, increased cash burn rate, and doubts about the company's ability to continue as a going concern. Regulatory delays and competitive pressures further exacerbate these issues. The Q&A section reveals management's lack of clarity on future customer uptake and test volumes, adding to uncertainties. Despite the potential for additional proceeds from warrant exercises, the overall sentiment is negative due to financial struggles, market competition, and regulatory hurdles. The stock is likely to experience a negative movement of -2% to -8% over the next two weeks.
People Also Watch

PSIG
PS International Group Ltd
0.380
USD
+1.06%

HAO
Haoxi Health Technology Ltd
1.159
USD
-2.61%

SOS
Sos Ltd
2.080
USD
+1.96%

CMCT
Creative Media & Community Trust Corporation
7.490
USD
+3.45%

LRHC
La Rosa Holdings
5.720
USD
-0.87%

BTBD
Bt Brands Inc
1.600
USD
-3.61%

BCDA
BioCardia Inc
1.890
USD
+1.61%

JAGX
Jaguar Health Inc
2.070
USD
-20.08%
FAQ

What were the key highlights of APDN’s latest earnings report for FY2025Q2?
APDN reported its FY2025Q2 earnings on 2025-05-15, showcasing a revenue of 983.37K against an estimate of 1.19M, resulting in a -17.02% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a -2.94% price change on the earnings day and a -1.09% change over the next five days, reflecting market reactions to the results.

How did APDN’s stock price react after the FY2025Q2 earnings release?

What are the revenue and EPS estimates for APDN for 2025/Q3?

How does APDN’s stock price correlate with earnings forecast revisions?

What should investors expect from APDN’s next earnings report?
